Department of Pediatrics and Adolescent Medicine and Department of Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N, Denmark.
Department of Pediatrics, Aalborg University Hospital, Reberbansgade 15, 9000, Aalborg, Denmark.
Eur J Pediatr. 2018 Sep;177(9):1399-1405. doi: 10.1007/s00431-018-3132-z. Epub 2018 Mar 28.
Congenital nephrogenic diabetes insipidus (CNDI) is characterized by the reduced ability of renal collecting duct cells to reabsorb water in response to the antidiuretic effect of vasopressin. Chronic polyuria and polydipsia are the hallmarks of the disease. Approximately 90% of all patients with CNDI have X-linked inherited disease caused by variants in the arginine vasopressin receptor 2 (AVPR2) gene. We present genetic findings in 34 individuals from 19 kindreds including one or more family members with CNDI. Coding regions of AVPR2 were sequenced bi-directionally. We identified eight novel disease-causing variants in AVPR2, p.Arg68Alafs124, p.Ser171Arg, p.Gln174Pro, p.Trp200Arg, p.Gly201Cys, p.Gly220Arg, p.Val226Glu, and p.Gln291Pro in nine kindreds. In all three families with more than one affected individual, the novel variants segregated with the disease. We also identified eight recurrent disease-causing variants, p.Val88Met, p.Leu111Valfs80, p.Arg113Trp, p.Tyr124*, p.Ser167Leu, p.Thr207Asn, p.Arg247Alafs12, and p.Arg337 in ten kindreds. Our findings contribute to the growing list of AVPR2 variants causing X-linked CNDI.
Being a rapid diagnostic tool for CNDI, direct sequencing of AVPR2 should be encouraged in newborns with familial predisposition to CNDI. What is Known: • Disease-causing variants in AVPR2 cause X-linked congenital nephrogenic diabetes insipidus (CNDI). • DNA sequencing of AVPR2 is rapid, facilitates differential diagnosis, early intervention, and genetic diagnosis thus reducing morbidity in CNDI. What is New: • We identified eight novel disease-causing variants in AVPR2: p.Arg68Alafs*124, p.Ser171Arg, p.Gln174Pro, p.Trp200Arg, p.Gly201Cys, p.Gly220Arg, p.Val226Glu, and p.Gln291Pro, thereby adding to the growing list of AVPR2 disease-causing variants and emphasizing the importance of genetic testing in CNDI.
先天性肾性尿崩症(CNDI)的特征是肾脏集合管细胞对血管加压素的抗利尿作用的再吸收水的能力降低。慢性多尿和多饮是该疾病的标志。大约 90%的所有 CNDI 患者都有 X 连锁遗传性疾病,由精氨酸加压素受体 2(AVPR2)基因的变异引起。我们提出了 19 个家系中 34 个人的遗传发现,其中包括一个或多个有 CNDI 的家族成员。AVPR2 的编码区进行了双向测序。我们在 9 个家系中发现了 8 个新的致病变异,即 AVPR2 的 p.Arg68Alafs124、p.Ser171Arg、p.Gln174Pro、p.Trp200Arg、p.Gly201Cys、p.Gly220Arg、p.Val226Glu 和 p.Gln291Pro。在 3 个有一个以上受影响个体的家族中,新的变异与疾病分离。我们还发现了 8 个复发性致病变异,即 p.Val88Met、p.Leu111Valfs80、p.Arg113Trp、p.Tyr124*、p.Ser167Leu、p.Thr207Asn、p.Arg247Alafs12 和 p.Arg337,在 10 个家系中发现了 8 个复发性致病变异。我们的发现有助于增加导致 X 连锁 CNDI 的 AVPR2 变异列表。
作为 CNDI 的快速诊断工具,应鼓励在有 CNDI 家族易感性的新生儿中直接对 AVPR2 进行测序。
•AVPR2 中的致病变异导致 X 连锁先天性肾性尿崩症(CNDI)。
•AVPR2 的 DNA 测序快速,有助于鉴别诊断、早期干预和遗传诊断,从而降低 CNDI 的发病率。
•我们在 AVPR2 中发现了 8 个新的致病变异,即 p.Arg68Alafs*124、p.Ser171Arg、p.Gln174Pro、p.Trp200Arg、p.Gly201Cys、p.Gly220Arg、p.Val226Glu 和 p.Gln291Pro,从而增加了 AVPR2 致病变异的列表,并强调了 CNDI 中遗传检测的重要性。